307 related articles for article (PubMed ID: 27516122)
1. Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.
Lyon TD; Turner RM; Yabes JG; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
Urology; 2016 Nov; 97():153-159. PubMed ID: 27516122
[TBL] [Abstract][Full Text] [Related]
2. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
3. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
[TBL] [Abstract][Full Text] [Related]
4. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
5. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.
Mass AY; Agalliu I; Laze J; Lepor H
J Urol; 2012 Sep; 188(3):786-91. PubMed ID: 22818136
[TBL] [Abstract][Full Text] [Related]
6. Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy.
DeLancey JO; Wood DP; He C; Montgomery JS; Weizer AZ; Miller DC; Jacobs BL; Montie JE; Hollenbeck BK; Skolarus TA
Urology; 2013 Feb; 81(2):354-7. PubMed ID: 23374801
[TBL] [Abstract][Full Text] [Related]
7. Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
Llukani E; Lepor H
BJU Int; 2017 Oct; 120(4):505-510. PubMed ID: 28220652
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
9. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy.
Rieken M; Kluth LA; Xylinas E; Seitz C; Fajkovic H; Karakiewicz PI; Lotan Y; Briganti A; Loidl W; Faison T; Crivelli JJ; Scherr DS; Bachmann A; Tewari AK; Kautzky-Willer A; Pummer K; Shariat SF
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):367-71. PubMed ID: 23999669
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
11. Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer.
Ishak-Howard MB; Okoth LA; Cooney KA
Urology; 2014 Jun; 83(6):1356-61. PubMed ID: 24745796
[TBL] [Abstract][Full Text] [Related]
12. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
[TBL] [Abstract][Full Text] [Related]
13. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
14. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Danzig MR; Kotamarti S; Ghandour RA; Rothberg MB; Dubow BP; Benson MC; Badani KK; McKiernan JM
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):63-8. PubMed ID: 25403419
[TBL] [Abstract][Full Text] [Related]
15. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
Aminsharifi A; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Polascik TJ; Freedland SJ
Clin Genitourin Cancer; 2019 Feb; 17(1):e140-e149. PubMed ID: 30366879
[TBL] [Abstract][Full Text] [Related]
16. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
17. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
[TBL] [Abstract][Full Text] [Related]
18. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
Liesenfeld L; Kron M; Gschwend JE; Herkommer K
J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
[TBL] [Abstract][Full Text] [Related]
20. The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.
Yamoah K; Zeigler-Johnson CM; Jeffers A; Malkowicz B; Spangler E; Park JY; Whittemore A; Rebbeck TR
BMC Cancer; 2016 Jul; 16():557. PubMed ID: 27473687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
